Journal
JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY
Volume 6, Issue 9-10, Pages 2991-2995Publisher
AMER SCIENTIFIC PUBLISHERS
DOI: 10.1166/jnn.2006.457
Keywords
solid lipid nanoparticles (SLN); antitumour drugs; methotrexate and drug targeting
Ask authors/readers for more resources
Solid Lipid Nanoparticles (SLN) containing Methotrexate (MTX), an anticancer drug for intravenous administration was formulated and characterized. The SLN dispersions with MTX, stearic acid, and soya lecithin in the ratio of 1:4:1, 1:4:1.5, and 1:4:2, sodium taurodeoxycholate and distilled water were prepared by micro emulsification solidification method. The results show that the prepared MTX-SLN particles (with MTX-Stearic acid-Soya lecithin-1:4:2) have an average size of 270 nm with 51.3% drug entrapment. The in-vitro release was attained up to 15th h. The pharmacokinetic study reveals that the half-life and MRT of SLNs were higher than MTX solution. The life span of EAC (Ehrlich Ascite Carcinoma) bearing mice was increased when treated with MTX-SLNs (Methotrexate nanoparticles). These results clearly indicate that SLNs are a promising sustained release drug targeting system for lipophilic antitumour drugs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available